Project Grant R03CA282955
Award Date
9/20/24
Completion Date
8/31/26
Dollars Obligated
$189K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $794,530 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Sloan-Kettering Institute for Cancer Research to conduct a phase IIb randomized controlled trial evaluating the efficacy of time-restricted eating to reduce weight and improve markers of cardiometabolic risk in 300 radiation-exposed survivors of childhood cancer with overweight/obesity. The study will leverage novel mHealth technology to deliver a remote,...
The National Cancer Institute (NCI) awarded a $396,061 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Missouri at Kansas City (UMKC). The grant, running from August 2024 to July 2026, aims to assess the potential therapeutic efficacy of newly synthesized boron-based inhibitors of the Hypoxia-Inducible Factor (HIF) pathway as a treatment strategy for renal cell carcinoma (RCC). Specifically, the project will (1) determine the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research by the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, spanning 2 years from February 2025 to January 2027, will fund genetic and pharmacological studies to assess the sensitivity of TRCC cells to CDK4/6...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), supports research to investigate the role of the Ran guanine exchange factor RCC1 in driving progression of pancreatic ductal adenocarcinoma (PDAC). The $103,948 award to Wayne State University aims to understand how RCC1 alters PDAC metabolic activity and mRNA processing to promote tumor progression, as well as evaluate the impact of RCC1...
The National Cancer Institute awarded a $546,349 Project Grant under the Cancer Biology Research (CFDA 93.396) program to The University of Texas Southwestern Medical Center to conduct research on the role of the von Hippel-Lindau (VHL) tumor suppressor in regulating gene expression through N6-methyladenosine (m6A) modification of mRNA in clear cell renal cell carcinoma (ccRCC). The research aims to determine the molecular mechanism by which VHL regulates m6A modification, and to examine the...
This $371,905 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of Florida to investigate the role of the protein Angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (ccRCC). The research aims to define ANGPTL4's function in the tumor microenvironment and its impact on ccRCC progression, metastasis, and vascularization. It will also test the efficacy of combining anti-ANGPTL4 antibodies with immune...
This Project Grant award from the National Cancer Institute (NCI), under the CFDA program 93.394 Cancer Detection and Diagnosis Research, provides $927,997.00 to Lagrange Scientific LLC to develop a prognostic assay for metastatic clear cell renal cell carcinoma (CCRCC). The goal is to identify a panel of metabolite biomarkers that can accurately predict early progression to metastasis in CCRCC patients, enabling earlier initiation of systemic therapy. The award will support further...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Brigham & Women's Hospital Inc. provides $358,000 in funding from August 1, 2024 to July 31, 2026. The project aims to characterize and address the issue of nonresponse in patient-reported outcome (PRO) data collected as part of routine cancer care. Specifically, the research will (1) examine nonresponse patterns across clinic, provider, and patient levels, (2) identify...
This National Cancer Institute (NCI) Cancer Research Manpower (CFDA 93.398) Project Grant award of $165,883 to Brigham & Women's Hospital Inc. aims to integrate molecular data into epidemiology studies to address gaps in understanding hepatocellular carcinoma (HCC) risk and improving risk assessment. The principal investigator, Dr. Xinyuan (Cindy) Zhang, will leverage resources from eight population-based prospective cohorts to: Examine pre-diagnostic plasma proteomics of incident HCC...